Quantcast

Latest Sulfoxides Stories

e1c5d5999898b09b579ed6902146d9e11
2010-05-11 06:45:00

The results of several studies released on Monday are suggesting that certain heartburn medicines may be doing more harm than good. Serious side effects could arise and it has been recommended that people use the drugs with caution. AstraZeneca's Nexium and Prilosec brands are among the drugs that could be harmful to health. While the drugs are helpful to the right patients, they can increase the risk of fractures in post-menopausal women and cause bacterial infections in many patients,...

2010-05-05 08:00:00

NEW ORLEANS, May 5 /PRNewswire/ -- What: Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation. Takeda recently announced that the product trade name for dexlansoprazole in the United States would be changed to DEXILANT from KAPIDEX(TM) (dexlansoprazole). The medical community...

2010-04-30 22:01:00

WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration (FDA) has approved VIMOVO(TM)( )(naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.(1) VIMOVO, co-developed by POZEN Inc....

2010-04-26 08:00:00

DEERFIELD, Ill., April 26 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that DEXILANT(TM) (dexlansoprazole) delayed release capsules are now available in United States (U.S.) pharmacies. Takeda recently announced that the product trade name for dexlansoprazole in the U.S. would be changed from KAPIDEX(TM) to DEXILANT. The formulation, indication and approved dosages of DEXILANT remain the same as that of KAPIDEX, which was originally approved by the U.S. Food...

2010-04-05 15:10:00

FRAZER, Pa., April 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon. Cephalon Chairman and CEO Frank Baldino Jr., Ph.D., said "We are fortunate to have the opportunity to advance CINQUIL(TM) (reslizumab) into Phase III studies for patients with eosinophilic asthma. CINQUIL, in addition to our...

2010-03-18 07:59:00

ROCKVILLE, Md., March 15 /PRNewswire-USNewswire/ -- Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health. The study also...

2010-03-04 10:12:00

DEERFIELD, Ill., March 4 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX(TM) (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT(TM) (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. After receiving reports of dispensing errors between KAPIDEX...

2010-02-23 07:00:00

FRAZER, Pa. and MALVERN, Pa., Feb. 23 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma. A Phase II clinical trial of Ception's lead compound, CINQUIL(TM) (reslizumab), in 106 patients demonstrated improved asthma control in adult patients with moderate to severe asthma and eosinophilic airway...

2010-02-09 08:00:00

DEERFIELD, Ill., Feb. 9 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated...

2010-02-01 06:00:00

FRAZER, Pa., AESCH, Switzerland, and MAISONS-ALFORT, France, Feb. 1 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company. Mepha has specific expertise in innovative dosage formulations and markets both generic and branded generic products. The acquisition diversifies the company's business mix, doubles the size of its international...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin